Findings from a year-long observational study
A 12-month observational study has reported that adding the anti-seizure medicine cenobamate to existing treatment in young adults with tuberous sclerosis complex was linked to better executive function, improved quality of life and reduced caregiver stress. At the same time, measures of overall cognition and adaptive behaviour did not show decline during the follow-up period.
The report was highlighted by the European Medical Journal on February 8, 2026.
What the study assessed
Tuberous sclerosis complex is a genetic condition that can involve multiple organs and is commonly associated with epilepsy and neurodevelopmental challenges. Because seizure control and side effects of medicines can influence daily functioning, researchers often track not only seizure-related outcomes but also cognitive performance, independence in everyday activities and caregiver burden.
In this observational study, investigators followed a group of young adults with tuberous sclerosis complex for one year after cenobamate was introduced as an add-on to their ongoing therapy. The focus was on changes in cognitive domains and day-to-day functioning rather than on acute, short-term effects.
Executive function and quality of life changes
According to the summary of results, executive function improved over the 12 months. Executive function typically refers to skills used for planning, organising, focusing attention, managing tasks and regulating behaviour. Changes in these abilities can affect performance in education, work and independent living.
The study also recorded an improvement in quality of life. While the report did not provide a breakdown of individual domains, quality-of-life measures generally capture a person’s perceived wellbeing, including physical, emotional and social functioning.
Caregiver stress and stability in broader measures
Caregiver stress decreased during the observation period. Caregiver stress is often shaped by seizure control, behavioural issues, daily care requirements and the practical demands of managing a chronic condition.
Importantly, the study found that overall cognition remained stable across the year. Adaptive behaviour—skills related to daily living such as communication, self-care and social interaction—also stayed stable. Stability in these areas may be relevant in conditions where cognitive or functional decline can be a concern for families and clinicians.
How to interpret the results
The findings come from an observational study, which tracks outcomes in real-world settings without assigning treatments at random. Such studies can provide useful information on how therapies perform outside controlled trials, but they do not by themselves establish cause and effect.
The European Medical Journal report described the results as indicating potential benefits of add-on cenobamate for executive function, quality of life and caregiver burden in young adults with tuberous sclerosis complex, alongside stable overall cognition and adaptive behaviour over 12 months.